Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Hanna Kortejärvi"'
Publikováno v:
Exploratory Research in Clinical and Social Pharmacy, Vol 5, Iss , Pp 100114- (2022)
Background: The ageing population with multiple conditions and complex health needs has forced healthcare systems to rethink the optimal way of delivering services. Instead of trying to manage numerous diseases in a siloed approach, the emphasis shou
Externí odkaz:
https://doaj.org/article/5358e9516c664c6ca07e8075e55bc225
Autor:
Jukka Ronkainen, Raisa Laaksonen, Nelli Äijö-Jensen, Marjo Yliperttula, Marja Blom, Hanna Kortejärvi, Heini Kari
Publikováno v:
Research in Social and Administrative Pharmacy. 18:3004-3012
Background There is a need for effective and cost-effective interprofessional care models that support older people to maintain their quality of life (QoL) and physical performance to live longer independently in their own homes. Objectives The objec
The aim of our study was to justify substitution of dissolution analysis for NIR measurement of Toremifene 80 mg tablets. We studied implementation of a NIRS method by integrating the method development to discrimination power of the dissolution meth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c91c374719594751faf46b7f1f4b65c6
http://hdl.handle.net/10138/339628
http://hdl.handle.net/10138/339628
Publikováno v:
British Journal of Clinical Pharmacology. 84:2048-2058
Aims The aim of this study is to evaluate how critical patient involvement is in pharmacist-led clinical medication reviews and in identifying the most significant clinical drug-related problems (DRPs). Methods Pharmacist-led clinical medication revi
Autor:
Ramzi Shawahna, Arto Urtti, Hanna Kortejärvi, Marjo Yliperttula, Jussi Malkki, Jean Michel Scherrmann
Publikováno v:
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 131
Autor:
Marjo Yliperttula, Jussi Malkki, Arto Urtti, Hanna Kortejärvi, Jean Michel Scherrmann, Ramzi Shawahna
Publikováno v:
European Journal of Pharmaceutical Sciences. 61:18-26
In this study, a pharmacokinetic simulation model was used to explore the dissolution acceptance criteria for BCS I and III biowaivers and to examine the risk of MDR-1 efflux transporter on bioequivalence of substrates. The compartmental absorption a
Autor:
Heli Kangas, Hanna Kortejärvi, Veli Pekka Tanninen, Paula Lehto, Anni Liimatainen, Jouni Hirvonen, Leena Peltonen, Krista Ojala
Publikováno v:
European Journal of Pharmaceutics and Biopharmaceutics. 78:531-538
The usefulness of selected conventional surfactant media to enhance dissolution of BCS class II drugs similarly to fasted state simulated intestinal fluid (FaSSIF) and to predict the absorption of drugs in vivo was evaluated. Dissolution behavior of
Publikováno v:
Journal of Pharmaceutical Sciences. 99:621-625
Currently, the EMEA, FDA, and WHO as regulatory authorities accept rapidly dissolving (>85% dissolved in 30 min) biopharmaceutics classification system (BCS) I drug products for biowaiver candidates. In the draft EMEA guideline the requirement has be
Publikováno v:
European Journal of Pharmaceutical Sciences. 30:155-166
In vitro dissolution tests can be used to waive in vivo bioequivalency studies (biowaiver), if drug has high solubility and high permeability according to biopharmaceutics classification system (BCS I). Then absorption of BCS I drugs is not dependent
Autor:
Jaakko Aaltonen, Leena Christiansen, Hanna Kortejärvi, Jouni Hirvonen, Jukka Rantanen, Leena Peltonen, Paula Heinänen, Jouko Yliruusi, Veli Pekka Tanninen
Publikováno v:
Journal of Pharmaceutical Sciences. 95:2730-2737
In this study, solvent-mediated phase transformations of theophylline (TP) and nitrofurantoin (NF) were measured in a channel flow intrinsic dissolution test system. The test set-up comprised simultaneous measurement of drug concentration in the diss